PMID- 28599663
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20240326
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 12
IP  - 1
DP  - 2017 Jun 9
TI  - Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: 
      preliminary results of the Oscar Lambret Center.
PG  - 95
LID - 10.1186/s13014-017-0833-9 [doi]
LID - 95
AB  - BACKGROUND: Currently, there is no standard option for local salvage treatment 
      for local prostate cancer recurrence after radiotherapy. Our objective was to 
      investigate the feasibility and efficiency of Robotic Stereotactic Body Radiation 
      Therapy (SBRT) in this clinical setting. METHODS/MATERIALS: We retrospectively 
      reviewed patients who were treated at our institution with SBRT for local 
      prostate cancer recurrence after External Beam Radiation Therapy (EBRT) or 
      brachytherapy. Multidisciplinary staff approved the treatment, and recurrence was 
      biopsy-proven when feasible. A dose of 36 Gy was prescribed in six fractions. 
      Treatment was delivered every other day. RESULTS: Between August 2011 and 
      February 2014, 23 patients were treated with SBRT for intra-prostate cancer 
      recurrence with a median follow up of 22 months (6 to 40). Twenty patients had 
      biopsy-proven recurrence. For 19 patients, EBRT was the initial treatment and in 
      four patients, brachytherapy was the initial treatment; the median relapse-time 
      from initial treatment was 65 months (28 to 150). At relapse, 10 patients had an 
      extra-capsular extension. Fourteen patients were treated with androgen 
      deprivation that could be stopped after a median of 1 month after SBRT (range 
      0-24). A PSA decrease occurred in 82.6% of the patients after SBRT. The 2-year 
      disease-free survival and overall survival rates were 54 and 100%, respectively. 
      Disease progression was observed for nine patients (39.1%) (five local, three 
      metastatic and one nodal progression) after a median of 20 months (7-40 months). 
      The median nadir PSA was 0.35 ng/ml and was achieved after a median of 8 months 
      (1 to 30) after treatment. We observed no grade 4 or 5 toxicity. Two patients 
      presented with grade 3 toxicities (two Cystitis and one neuralgia). Other 
      toxicities included urinary toxicities (five grade 2 and nine grade 1) and rectal 
      toxicities (two grade 2 and two grade 1). CONCLUSION: SBRT for local prostate 
      cancer recurrence seems feasible and well tolerated with a short follow up. 
      Prospective evaluation is needed.
FAU - Leroy, Thomas
AU  - Leroy T
AD  - Department of Radiation Oncology, Centre de Lutte Contre le Cancer Oscar Lambret, 
      3 rue Frederic Combemale, 59020, Lille cedex, France.
FAU - Lacornerie, Thomas
AU  - Lacornerie T
AD  - Department of Radiation Physics, Centre de Lutte Contre le Cancer Oscar Lambret, 
      3 rue Frederic Combemale, 59020, Lille cedex, France.
FAU - Bogart, Emilie
AU  - Bogart E
AD  - Department of Statistic, Centre de Lutte Contre le Cancer Oscar Lambret, 3 rue 
      Frederic Combemale, 59020, Lille cedex, France.
FAU - Nickers, Philippe
AU  - Nickers P
AD  - Department of Radiation Oncology, Centre de Lutte Contre le Cancer Oscar Lambret, 
      3 rue Frederic Combemale, 59020, Lille cedex, France.
FAU - Lartigau, Eric
AU  - Lartigau E
AD  - Department of Radiation Oncology, Centre de Lutte Contre le Cancer Oscar Lambret, 
      3 rue Frederic Combemale, 59020, Lille cedex, France.
AD  - Universite de Lille-CRIStAL UMR 9189, 59650, Villeneuve d'Ascq, France.
FAU - Pasquier, David
AU  - Pasquier D
AUID- ORCID: 0000-0001-6019-7309
AD  - Department of Radiation Oncology, Centre de Lutte Contre le Cancer Oscar Lambret, 
      3 rue Frederic Combemale, 59020, Lille cedex, France. d-pasquier@o-lambret.fr.
AD  - Universite de Lille-CRIStAL UMR 9189, 59650, Villeneuve d'Ascq, France. 
      d-pasquier@o-lambret.fr.
LA  - eng
PT  - Journal Article
DEP - 20170609
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Brachytherapy/*adverse effects
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/diagnosis/*surgery
MH  - Organs at Risk/*radiation effects
MH  - Prostatic Neoplasms/pathology/*radiotherapy
MH  - *Radiosurgery
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Retrospective Studies
MH  - Robotic Surgical Procedures/*methods
MH  - *Salvage Therapy
PMC - PMC5466739
OTO - NOTNLM
OT  - Prostate cancer
OT  - Recurrence
OT  - Stereotactic radiation body therapy
EDAT- 2017/06/11 06:00
MHDA- 2018/03/27 06:00
PMCR- 2017/06/09
CRDT- 2017/06/11 06:00
PHST- 2016/12/11 00:00 [received]
PHST- 2017/06/02 00:00 [accepted]
PHST- 2017/06/11 06:00 [entrez]
PHST- 2017/06/11 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/06/09 00:00 [pmc-release]
AID - 10.1186/s13014-017-0833-9 [pii]
AID - 833 [pii]
AID - 10.1186/s13014-017-0833-9 [doi]
PST - epublish
SO  - Radiat Oncol. 2017 Jun 9;12(1):95. doi: 10.1186/s13014-017-0833-9.